330 related articles for article (PubMed ID: 23812503)
1. MICE models: superior to the HERG model in predicting Torsade de Pointes.
Kramer J; Obejero-Paz CA; Myatt G; Kuryshev YA; Bruening-Wright A; Verducci JS; Brown AM
Sci Rep; 2013; 3():2100. PubMed ID: 23812503
[TBL] [Abstract][Full Text] [Related]
2. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Mirams GR; Cui Y; Sher A; Fink M; Cooper J; Heath BM; McMahon NC; Gavaghan DJ; Noble D
Cardiovasc Res; 2011 Jul; 91(1):53-61. PubMed ID: 21300721
[TBL] [Abstract][Full Text] [Related]
3. Use of high throughput ion channel profiling and statistical modeling to predict off-target arrhythmia risk - One pharma's experience and perspective.
Watt ED; Lee T; Feng SL; Kilfoil P; Ackley D; Keefer C; Wisialowski T; Jenkinson S
J Pharmacol Toxicol Methods; 2022; 118():107213. PubMed ID: 36084863
[TBL] [Abstract][Full Text] [Related]
4. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
5. Recording hERG potassium currents and assessing the effects of compounds using the whole-cell patch-clamp technique.
Helliwell RM
Methods Mol Biol; 2008; 491():279-95. PubMed ID: 18998101
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
Crumb WJ; Vicente J; Johannesen L; Strauss DG
J Pharmacol Toxicol Methods; 2016; 81():251-62. PubMed ID: 27060526
[TBL] [Abstract][Full Text] [Related]
7. Development of models for predicting Torsade de Pointes cardiac arrhythmias using perceptron neural networks.
Sharifi M; Buzatu D; Harris S; Wilkes J
BMC Bioinformatics; 2017 Dec; 18(Suppl 14):497. PubMed ID: 29297274
[TBL] [Abstract][Full Text] [Related]
8. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
10. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
Zünkler BJ
Pharmacol Ther; 2006 Oct; 112(1):12-37. PubMed ID: 16647758
[TBL] [Abstract][Full Text] [Related]
11. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
12. Observations on conducting whole-cell patch clamping of the hERG cardiac K
Kang J; Luo Y; Searles M; Rampe D
J Appl Toxicol; 2017 Apr; 37(4):445-453. PubMed ID: 27553911
[TBL] [Abstract][Full Text] [Related]
13. Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart.
Wu L; Rajamani S; Li H; January CT; Shryock JC; Belardinelli L
Am J Physiol Heart Circ Physiol; 2009 Sep; 297(3):H1048-57. PubMed ID: 19592609
[TBL] [Abstract][Full Text] [Related]
14. Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels.
Testai L; Bianucci AM; Massarelli I; Breschi MC; Martinotti E; Calderone V
Curr Med Chem; 2004 Oct; 11(20):2691-706. PubMed ID: 15544470
[TBL] [Abstract][Full Text] [Related]
15. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
Gintant GA; Su Z; Martin RL; Cox BF
Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
[TBL] [Abstract][Full Text] [Related]
16. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Hancox JC; McPate MJ; El Harchi A; Zhang YH
Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
[TBL] [Abstract][Full Text] [Related]
17. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
[TBL] [Abstract][Full Text] [Related]
18. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.
Calderone V; Testai L; Martinotti E; Del Tacca M; Breschi MC
J Pharm Pharmacol; 2005 Feb; 57(2):151-61. PubMed ID: 15720777
[TBL] [Abstract][Full Text] [Related]
20. Arrhythmogenicity of Anti-Ro/SSA Antibodies in Patients With Torsades de Pointes.
Lazzerini PE; Yue Y; Srivastava U; Fabris F; Capecchi PL; Bertolozzi I; Bacarelli MR; Morozzi G; Acampa M; Natale M; El-Sherif N; Galeazzi M; Laghi-Pasini F; Boutjdir M
Circ Arrhythm Electrophysiol; 2016 Apr; 9(4):e003419. PubMed ID: 27030700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
